Cargando…

A 32-Year-Old Man with Persistent Olfactory Dysfunction Following COVID-19 Whose Recovery Was Evaluated by Retronasal Olfactory Testing

Patient: Male, 32-year-old Final Diagnosis: Olfactory impairment caused by COVID-19 Symptoms: Olfactory impairment Medication:— Clinical Procedure: — Specialty: Otolaryngology OBJECTIVE: Unusual clinical course BACKGROUND: Anosmia, which is loss of smell, is a recognized complication of coronavirus...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Kojiro, Tanaka, Yoshihito, Kamimura, Sawa, Suzaki, Isao, Suzuki, Emiko, Kobayashi, Hitome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475494/
https://www.ncbi.nlm.nih.gov/pubmed/36089753
http://dx.doi.org/10.12659/AJCR.936496
Descripción
Sumario:Patient: Male, 32-year-old Final Diagnosis: Olfactory impairment caused by COVID-19 Symptoms: Olfactory impairment Medication:— Clinical Procedure: — Specialty: Otolaryngology OBJECTIVE: Unusual clinical course BACKGROUND: Anosmia, which is loss of smell, is a recognized complication of coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may persist after recovery from infection. Retronasal olfactory testing includes both subjective questionnaires and physiological tests that can be used to evaluate recovery of smell. This report presents the case of a 32-year-old man with persistent loss of smell following COVID-19 whose recovery was evaluated by retronasal olfactory testing. CASE REPORT: The patient was a 32-year-old man with confirmed SARS-CoV-2 infection. He was aware of his olfactory dys-function. Using the orthonasal test, a T&T Olfactometer 2 months after disease onset showed an olfactory threshold score of 2.2 points (mild decrease) and olfactory identification result of 3.4 points (moderate decrease). However, the retronasal intravenous olfactory test showed no response, indicating severe olfactory dysfunction. After 3 months of olfactory training and therapy with steroidal nasal drops (Fluticasone Furoate, 27.5 µg/day) and oral vitamins (Mecobalamin, 1500 µg/day), the patient’s orthonasal test olfactory threshold score improved to 0.6 points (normal), and his olfactory identification result improved to 1.2 points (mild decrease). Although the retronasal intravenous olfactory test showed a weak response, a reaction did occur. At this time, the patient did not report any improvement in his symptoms. CONCLUSIONS: This report has shown that in cases of persistent anosmia following COVID-19, retronasal olfactory testing can be used to evaluate recovery of the sense of smell.